112 related articles for article (PubMed ID: 34659195)
21. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
22. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
Zehbe I; Kaufmann AM; Schmidt M; Hohn H; Maeurer MJ
J Immunother; 2007; 30(5):523-32. PubMed ID: 17589293
[TBL] [Abstract][Full Text] [Related]
24. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells.
Wang X; Santin AD; Bellone S; Gupta S; Nakagawa M
Cancer Immunol Immunother; 2009 Feb; 58(2):301-8. PubMed ID: 18446336
[TBL] [Abstract][Full Text] [Related]
25. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.
Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729
[TBL] [Abstract][Full Text] [Related]
26. CD40 Accelerates the Antigen-Specific Stem-Like Memory CD8
Zhang Y; Wang N; Ding M; Yang Y; Wang Z; Huang L; Zhu W; Mellor AL; Hou X; Zhou C; Yan R; Wang W; Wu S
Front Immunol; 2020; 11():1012. PubMed ID: 32536922
[TBL] [Abstract][Full Text] [Related]
27. Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination.
Abdulrahman Z; de Miranda N; van Esch EMG; de Vos van Steenwijk PJ; Nijman HW; J P Welters M; van Poelgeest MIE; van der Burg SH
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169871
[TBL] [Abstract][Full Text] [Related]
28. Significance of p53-Binding Protein 1 Nuclear Foci in Cervical Squamous Intraepithelial Lesions: Association With High-Risk Human Papillomavirus Infection and P16
Kawashita S; Matsuda K; Kondo H; Kitajima Y; Hasegawa Y; Shimada T; Kitajima M; Miura K; Nakashima M; Masuzaki H
Cancer Control; 2020; 27(1):1073274819901170. PubMed ID: 32077330
[TBL] [Abstract][Full Text] [Related]
29. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
30. Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6.
Draper LM; Kwong ML; Gros A; Stevanović S; Tran E; Kerkar S; Raffeld M; Rosenberg SA; Hinrichs CS
Clin Cancer Res; 2015 Oct; 21(19):4431-9. PubMed ID: 26429982
[TBL] [Abstract][Full Text] [Related]
31. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
32. GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
Van Damme P; Bouillette-Marussig M; Hens A; De Coster I; Depuydt C; Goubier A; Van Tendeloo V; Cools N; Goossens H; Hercend T; Timmerman B; Bissery MC
Clin Cancer Res; 2016 Jul; 22(13):3238-48. PubMed ID: 27252412
[TBL] [Abstract][Full Text] [Related]
33. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
Lee YS; Lee CW; Song MJ; Ho EM; Kim CJ; Park TC; Kim TG; Park JS
Acta Obstet Gynecol Scand; 2011 Dec; 90(12):1350-6. PubMed ID: 21916856
[TBL] [Abstract][Full Text] [Related]
34. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging.
Lowy DR; Herrero R; Hildesheim A;
Lancet Oncol; 2015 May; 16(5):e226-33. PubMed ID: 25943067
[TBL] [Abstract][Full Text] [Related]
35. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.
Jemon K; Young V; Wilson M; McKee S; Ward V; Baird M; Young S; Hibma M
PLoS One; 2013; 8(6):e66866. PubMed ID: 23799135
[TBL] [Abstract][Full Text] [Related]
36. Anti-pulmonary metastases from cervical cancer responses induced by a human papillomavirus peptide vaccine adjuvanted with CpG-oligodeoxynucleotides in vivo.
Suo J; Yang Y; Che Y; Chen C; Lv X; Wang X
Int Immunopharmacol; 2021 Jan; 90():107203. PubMed ID: 33234417
[TBL] [Abstract][Full Text] [Related]
37. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.
de Vos van Steenwijk PJ; van Poelgeest MI; Ramwadhdoebe TH; Löwik MJ; Berends-van der Meer DM; van der Minne CE; Loof NM; Stynenbosch LF; Fathers LM; Valentijn AR; Oostendorp J; Osse EM; Fleuren GJ; Nooij L; Kagie MJ; Hellebrekers BW; Melief CJ; Welters MJ; van der Burg SH; Kenter GG
Cancer Immunol Immunother; 2014 Feb; 63(2):147-60. PubMed ID: 24233343
[TBL] [Abstract][Full Text] [Related]
38. CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients.
Díaz-Benítez CE; Navarro-Fuentes KR; Flores-Sosa JA; Juárez-Díaz J; Uribe-Salas FJ; Román-Basaure E; González-Mena LE; Alonso de Ruíz P; López-Estrada G; Lagunas-Martínez A; Bermúdez-Morales VH; Alcocer-González JM; Martínez-Barnetche J; Hernández-Pando R; Rosenstein Y; Moreno J; Madrid-Marina V
J Clin Immunol; 2009 Jul; 29(4):532-44. PubMed ID: 19259799
[TBL] [Abstract][Full Text] [Related]
39. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy.
Manzar GS; Alam MBE; Lynn EJ; Karpinets TV; Harris T; Lo D; Yoshida-Court K; Napravnik TC; Sammouri J; Lin D; Andring LM; Bronk J; Wu X; Sims TT; Mathew G; Schmeler KM; Eifel PJ; Jhingran A; Lin LL; Joyner MM; Zhang J; Futreal A; Klopp AH; Colbert LE
Brachytherapy; 2024; 23(2):123-135. PubMed ID: 38129211
[TBL] [Abstract][Full Text] [Related]
40. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
Litwin TR; Irvin SR; Chornock RL; Sahasrabuddhe VV; Stanley M; Wentzensen N
Br J Cancer; 2021 Feb; 124(4):831-841. PubMed ID: 33257839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
